NCT05089084Phase 3Completed

Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

Study sponsor: Arrowhead Pharmaceuticals

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2024-04-29Actual

Enrollment · participants75Actual

Source updated2026-06-05Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-06-05 · 1 field changed

Recruitment status changed

− Before

~~Active not recruiting~~

+ After

Completed

Check registry source

Posted 2026-01-12 · 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: Percent Change ~~from~~ Baseline in Fasting Triglycerides (TG) ~~at Month 10~~

+ After

Measure: Percent Change From Baseline at Month 10 in Fasting Triglycerides (TG)

Check registry source